OCT 23, 2020 8:30 AM PDT

FDA Gives Full Approval to Remdesivir to Treat COVID-19

WRITTEN BY: Annie Lennon

The US Food and Drug Administration (FDA) has approved antiviral drug Remdesivir, sold under the name ‘Velkury’, for use in adults and children aged 12 and above to treat COVID-19 infections requiring hospitalization. 

Previously, on May 1, 2020, Remdesivir had been given Emergency Use Authorization (EUA) by the FDA, making it available for the entire population while studies on its overall effectiveness were ongoing. As clinical trials assessing the drug’s safety in children are still underway, the FDA has revised the EUA for the drug to continue being used for hospitalized patients with suspected of lab-confirmed COVID-19 who are under the age of 12 and weigh at least 3.5 kg. 

The drug approval comes after the publication of a recent non-peer-reviewed preprint study by the World Health Organization (WHO) showing that Remdesivir, and three other drugs commonly used to treat COVID-19, had marginal effects on the mortality rate for COVID-19 patients. Causing some to doubt the effectiveness of the drug, Gilead Sciences, the pharmaceuritical company behind Remdesivir, warned that the results from the trials have yet to undergo the review process and thus should not be taken without a pinch of salt. 

Nevertheless, other studies have shown that usage of the drug does have some therapeutic effect. A recent study involving 1,062 volunteers, for example, showed that Remdesivir reduces average recovery times (defined as being discharged from hospital or no longer requiring supplemental oxygen or ongoing medical care) from 15 to 10 days. These results reflect early clinical trial results from both the US and China on the drug’s ability to treat COVID-19. 

Considering all available data, it seems that although Remdesivir has almost no effect on death rates, it has shown to be moderately effective in accelerating recovery times for COVID-19. As such, while it is no ‘cure’, it may nevertheless benefit patients recovering from the virus. 

 

Sources: DWFDAThe New York Times

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 30, 2020
Cancer
Chemokines Could be the Key in Controlling Glioma Stem Cells
SEP 30, 2020
Chemokines Could be the Key in Controlling Glioma Stem Cells
The transformation of a healthy cell into a cancerous one often comes with a slew of cellular signaling changes.  T ...
OCT 01, 2020
Cancer
Understanding in vivo Metabolomics: C13 Isotope Studies
OCT 01, 2020
Understanding in vivo Metabolomics: C13 Isotope Studies
One key to understanding cancer metabolomics lies in the ability to accurately replicate the natural environment of the ...
OCT 15, 2020
Neuroscience
Neurometabolism: A bold, new frontier
OCT 15, 2020
Neurometabolism: A bold, new frontier
Billions of neurons communicate with each other through trillions of synapses to create a functioning, unique system we ...
OCT 29, 2020
Cardiology
Treating Cardiovascular Calcification at the Source
OCT 29, 2020
Treating Cardiovascular Calcification at the Source
The term cardiovascular disease covers a broad array of health problems. Everyone tends to think of heart attacks or hyp ...
OCT 09, 2020
Technology
Deep Learning Advances Drug Design
OCT 09, 2020
Deep Learning Advances Drug Design
Computational data is advancing all areas of medicine and pharmaceutical drug development is certainly no exception. &nb ...
OCT 29, 2020
Drug Discovery & Development
Scientists Create Antibiotic from Komodo Dragon Blood
OCT 29, 2020
Scientists Create Antibiotic from Komodo Dragon Blood
Researchers from George Mason University in Washington DC have created a synthetic molecule from Komodo Dragon blood tha ...
Loading Comments...